AMGN - Eli Lilly Novo to lead $100B weight loss drug market in 2030: JPMorgan
2023-09-10 12:00:00 ET
More on Eli Lilly, Novo, etc.
- Novo Nordisk: Super Focused Pharma Company For The Long Run
- Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
- Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad?
- Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead
- Eli Lilly Q2: Dividends Don't Lie
- Novo Nordisk A/S 2023 Q2 - Results - Earnings Call Presentation
- Novo Nordisk A/S ( NVO ) Q2 2023 Earnings Call Transcript
- Eli Lilly: Q2 And 2023 Revised Guidance Impressive, But Key Is Wegovy Data
- Eli Lilly wins U.K. backing for diabetes drug Mounjaro
- Researchers study weight loss drugs in dementia and addiction
- Novo Nordisk announces limited launch of Wegovy in U.K.
- Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag
- Novo Nordisk briefly dethrones LVMH as EU's most valuable company
- Senators ask Novo Nordisk, Lilly, Sanofi for details on discount insulin programs
- Study finds Wegovy least cost-effective drug option for teen weight loss
- Novo Nordisk scoops up Embark Biotech amid foray into obesity
For further details see:
Eli Lilly, Novo to lead $100B weight loss drug market in 2030: JPMorgan